Nanobiotix SA Aktie

2,98 EUR -0,19 EUR -6,12 %

23.12.2024

STU

4,62 EUR -1,48 EUR -24,26 %

26.07.2024

LSE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.140,86 Mio. EUR

Div. Rendite0,00%

WKNA1J7EB

ISINFR0011341205

SymbolNNBXF

Nanobiotix SA Aktien News

Sortieren:Datum Meistgelesen

01.11.23GlobeNewswireNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

23.10.23GlobeNewswireNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

11.10.23GlobeNewswireVoting Rights and Shares Capital of the Company

04.10.23GlobeNewswireNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival o

29.09.23GlobeNewswireNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation O

28.09.23GlobeNewswireNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

26.09.23GlobeNewswireNANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

19.09.23GlobeNewswireNanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

13.09.23GlobeNewswireVoting Rights and Shares Capital of the Company

05.09.23GlobeNewswireNANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

31.08.23GlobeNewswireNANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

15.08.23GlobeNewswireNANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

04.08.23GlobeNewswireNANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

20.07.23GlobeNewswireVoting Rights and Shares Capital of the Company

19.07.23GlobeNewswireNANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

10.07.23GlobeNewswireNANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

08.06.23GlobeNewswireVoting Rights and Shares Capital of the Company

17.05.23GlobeNewswireNANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

05.05.23GlobeNewswireNANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

25.04.23GlobeNewswireNANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

17.04.23GlobeNewswireNANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

11.04.23GlobeNewswireVoting Rights and Shares Capital of the Company

27.03.23GlobeNewswireNanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

14.03.23GlobeNewswireNanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

14.02.23GlobeNewswireVoting Rights and Shares Capital of the Company

10.10.22BusinesswireNanobiotix: Voting Rights and Shares Capital of the Company

28.09.22BusinesswireNanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022

22.09.22BusinesswireNanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

21.09.22BusinesswireNanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

12.09.22BusinesswireNanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

08.09.22BusinesswireNanobiotix: Voting Rights and Shares Capital of the Company

07.09.22BusinesswireNANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

06.09.22BusinesswireNANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

31.08.22BusinesswireNanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

09.08.22BusinesswireNANOBIOTIX: Voting Rights and Shares Capital of the Company

13.07.22BusinesswireHalf-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont

08.07.22BusinesswireNanobiotix: Voting Rights and Shares Capital of the Company

09.06.22BusinesswireNANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

05.06.22BusinesswireNANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

02.06.22BusinesswireNANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022

Nanobiotix SA News

Nanobiotix SA News: auf dieser Seite finden Sie alle Nanobiotix SA News und Nachrichten zur Nanobiotix SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Nanobiotix SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Nanobiotix SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.